Oruka Therapeutics, Inc. (ORKA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Oruka Therapeutics, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 22 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 94.80 $ — 96% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -22.3%
- ROCE > 15% -25.8%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 46.8% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 335 m net cash passed
- Operating cash flow covers the profits of the last three years 43 m failed
- Return on capital at 15% or higher, or up versus two years ago -25.8% failed
- Insiders hold at least 10% or are net buyers 1.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 56.3% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.04 | -2.77 – -1.70 | 0 | -10.2% | 9 |
| 12/31/2027 | -2.49 | -4.12 – -1.64 | 0 | -22.2% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.49 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.99 | – | – | – | – | -19 | -19 |
| 2025: Q1 | -0.50 | – | 0 | – | – | -21 | -21 |
| 2025: Q2 | -0.58 | – | 0 | – | – | -23 | -23 |
| 2025: Q3 | -0.69 | – | 0 | – | – | -22 | -22 |
| 2025: Q4 | -0.54 | – | 0 | – | – | -23 | -23 |
| 2026: Q1 | -0.58 | – | 0 | – | – | -24 | -24 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | – | -17 | -16 | -391.73 | -15 | 22 | 25 |
| 2017 | – | -19 | -18 | -382.87 | -17 | 10 | 12 |
| 2018 | – | -8 | -8 | -123.73 | -8 | 6 | 7 |
| 2019 | – | -6 | -5 | -49.79 | -5 | 8 | 9 |
| 2020 | – | -10 | -10 | -2.07 | -8 | 47 | 50 |
| 2021 | – | -19 | -19 | -1.39 | -19 | 51 | 55 |
| 2022 | – | -10 | -10 | -0.69 | -11 | 42 | 43 |
| 2023 | – | -7 | -5 | -0.37 | – | 37 | 38 |
| 2024 | – | -88 | -84 | -4.99 | -58 | 382 | 396 |
| 2025 | 0 | -122 | -105 | -2.31 | -88 | 472 | 489 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Oruka Therapeutics, Inc., ein biopharmazeutisches Unternehmen im klinischen Stadium, konzentriert sich auf die Entwicklung neuartiger monoklonaler Antikörper-Therapeutika für Psoriasis (PsO) und andere entzündliche und immunologische (I&I) Indikationen.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 68 |
| Headquarters | Menlo Park, CA |
| Address | 855 Oak Grove Avenue, 94025 Menlo Park, United States |
| Phone | 650 606 7910 |
| Website | orukatx.com |
| IPO Date | 8. Aug 1997 |
| ISIN | US6876041087 |
| Stock Split | 1:12 on 09/03/2024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Lawrence Otto Klein Ph.D. | President, CEO & Director | 1983 |
| Paul T. Quinlan | General Counsel & Secretary | 1963 |
| Joana Goncalves M.D. | Chief Medical Officer | 1974 |
| Arjun Agarwal CPA | Senior VP of Finance & Treasurer | 1976 |
| Alan Lada | VP of IR & Capital Markets | – |
| Christopher Finch | Senior VP and Head of Business Development & Strategy | – |
| Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Goncalves Joana | Chief Medical Officer | Sell | 300 | 87.25 | 26,176 |
| 15. Jul 2026 | Goncalves Joana | Chief Medical Officer | Sell | 3,803 | 86.68 | 329,630 |
| 15. Jul 2026 | Goncalves Joana | Chief Medical Officer | Sell | 2,497 | 85.86 | 214,385 |
| 15. Jul 2026 | Goncalves Joana | Chief Medical Officer | Sell | 400 | 84.37 | 33,746 |
| 15. Jul 2026 | Goncalves Joana | Chief Medical Officer | Other | 3,500 | 7.80 | 27,300 |
| 13. Jul 2026 | Agarwal Arjun | Senior Vice President, Finance | Sell | 5,656 | 84.90 | 480,201 |
| 13. Jul 2026 | Agarwal Arjun | Senior Vice President, Finance | Sell | 3,743 | 84.26 | 315,369 |
| 13. Jul 2026 | Agarwal Arjun | Senior Vice President, Finance | Sell | 300 | 85.63 | 25,690 |
| 13. Jul 2026 | Agarwal Arjun | Senior Vice President, Finance | Other | 1,458 | 34.39 | 50,141 |
| 13. Jul 2026 | Agarwal Arjun | Senior Vice President, Finance | Other | 8,541 | 12.50 | 106,763 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.